Cornerstone Select Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.09M Buy
19,000
+393
+2% +$22.6K 0.46% 62
2026
Q1
$1.13M Sell
18,607
-1,963
-10% -$114K 0.71% 47
2025
Q4
$1.11M Sell
20,570
-2,546
-11% -$122K 0.77% 44
2025
Q3
$1.04M Sell
23,116
-5,376
-19% -$251K 0.77% 45
2025
Q2
$1.32M Sell
28,492
-686
-2% -$33.7K 1.16% 32
2025
Q1
$1.78M Buy
29,178
+568
+2% +$33.1K 1.69% 17
2024
Q4
$1.62M Buy
+28,610
New +$1.6M 1.56% 20

Other funds holding BMY

Cornerstone Select Advisors's BMY Position: Q2 2026 in Review

Cornerstone Select Advisors increased its Bristol-Myers Squibb (BMY) stake by 2.1% in Q2 2026, buying an estimated $22.6K and bringing the position to 19,000 shares worth $1.09M. The position accounts for 0.46% of the portfolio, ranked #62.

Cornerstone Select Advisors first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.78M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Cornerstone Select Advisors held 19,000 shares of Bristol-Myers Squibb worth $1.09M as of Q2 2026.
  • Cornerstone Select Advisors bought 393 Bristol-Myers Squibb shares in Q2 2026, an estimated $22.6K.
  • Bristol-Myers Squibb made up 0.46% of Cornerstone Select Advisors's portfolio in Q2 2026, its #62 holding.
  • Cornerstone Select Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
  • Cornerstone Select Advisors's Bristol-Myers Squibb position peaked at $1.78M in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Cornerstone Select Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.